FIELD: medicine; oncology.
SUBSTANCE: invention relates to medicine, namely to oncology; it can be used for the treatment of renal cell carcinoma. The method includes administration to a subject, which has renal cell carcinoma and has got preliminary therapy directed against a vascular endothelium growth factor (VEGF), of Lenvatinib and everolimus, if persisting and intolerable undesired reaction occurs, the Lenvatinib dose is reduced.
EFFECT: use of the invention allows for continuing treatment of renal cell carcinoma in occurrence of undesired reactions due to modification of a Lenvatinib dosage scheme.
20 cl, 3 dwg, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIOMARKERS FOR COMBINED THERAPY INCLUDING LENVATINIB AND EVEROLIMUS | 2016 |
|
RU2745060C2 |
| APILIMOD FOR USE IN TREATING RENAL CANCER | 2015 |
|
RU2727802C2 |
| COMPOSITIONS AND METHODS OF TREATMENT OR PREVENTION OF VASOMOTOR SYMPTOMS | 2018 |
|
RU2815402C2 |
| USE OF ERIBULIN AND LENVATINIB AS COMBINATION THERAPY FOR TREATMENT OF CANCER | 2014 |
|
RU2672585C2 |
| COMBINATION THERAPY FOR CANCER TREATMENT | 2014 |
|
RU2805145C2 |
| COMBINATION THERAPIES FOR TREATMENT OF HEPATOCELLULAR CARCINOMA | 2019 |
|
RU2787993C2 |
| COMBINATION THERAPY FOR TREATMENT OF CANCER | 2014 |
|
RU2680714C2 |
| USE OF COMPOUNDS IN TREATING FUNGAL INFECTIONS | 2021 |
|
RU2805930C1 |
| ANTITUMOUR THERAPEUTIC AGENT | 2016 |
|
RU2718048C2 |
| COMPOUNDS AND METHODS FOR TREATING FUNGAL INFECTIONS | 2021 |
|
RU2824066C1 |
